Niclosamide (olamine)

Niclosamide (BAY2353) olamine is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide olamin is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide olamin has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[2][3][5].

Product Specifications

CAS Number

[1420-04-8]

Product Name Alternative

BAY2353 (olamine)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Parasite; STAT

Type

Reference compound

Related Pathways

Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/niclosamide-olamine.html

Purity

98.66

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O.NCCO

Molecular Formula

C15H15Cl2N3O5

Molecular Weight

388.20

Precautions

H302, H315, H319, H335

References & Citations

[1]P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19 (2) :245-95.|[2]Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96.|[3]Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22 (14) :3458-66.|[4]Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1 (9) :454-9.|[5]Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48 (7) :2693-6.